NCT04694001 (INSPIRE) is a NA clinical trial of Use of the Atalante exoskeleton in Stroke, sponsored by Wandercraft.

Who is sponsoring NCT04694001?

NCT04694001 is sponsored by Wandercraft.

What drugs are being tested in NCT04694001?

Interventions in NCT04694001: Use of the Atalante exoskeleton.

What condition does NCT04694001 study?

NCT04694001 studies Stroke, Stroke, Acute, Stroke, Subacute, Chronic Stroke.

Is NCT04694001 still recruiting?

NCT04694001 is currently completed. Last updated 27 April 2022.

Last reviewed 2022-04-27 · How we verify

NCT04694001: INSPIRE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Use of the Atalante Exoskeleton in Patients Presenting an Hemiplegia Due to Cerebrovascular Accident

Completed NA Last updated 27 April 2022

What this trial tests

NA trial testing Use of the Atalante exoskeleton in Stroke in 40 participants. Completed in 28 March 2022.

Timeline

12 April 2021

Primary endpoint
28 March 2022

28 March 2022

Quick facts

Lead sponsor	Wandercraft
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	40
Start date	12 April 2021
Primary completion	28 March 2022
Estimated completion	28 March 2022
Sites	6 locations across Belgium, France, Luxembourg

Drugs / interventions tested

Use of the Atalante exoskeleton

Conditions studied

Stroke — all drugs for Stroke →
Stroke, Acute — all drugs for Stroke, Acute →
Stroke, Subacute — all drugs for Stroke, Subacute →
Chronic Stroke — all drugs for Chronic Stroke →

Sponsor

Wandercraft

Who can join

18 and older, any sex, with Stroke or Stroke, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The INSPIRE study is interventional, European, prospective, open, multicentric, each patient being his/her own control. It is conducted to assess the safety and performance of the Atalante exoskeleton system in patients presenting an hemiplegia due to cerebrovascular accident. The primary endpoint is defined by the reported adverse events. The study will include 40 patients and takes place in six rehabilitation centers (4 in France, 1 in Luxembourg, 1 in Belgium).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Hands-free Atalante exoskeleton in post-stroke gait and balance rehabilitation: a safety study.
Lejeune T, Nuic D, Dehem S, Previnaire JG, et al · · 2025 · cited 1× · PMID 40221748 · DOI 10.1186/s12984-025-01621-z
Safety and efficacy of the Atalante exoskeleton in the rehabilitation of French patients with amyotrophic lateral sclerosis: a prospective, monocentric, open, uncontrolled, interventional protocol, EXALS.
Trad G, Lenglet T, Ledoux I, Querin G, et al · · 2026 · PMID 41545051 · DOI 10.1136/bmjopen-2025-109620

Verify or expand the search:

Other trials of Use of the Atalante exoskeleton

Trials testing the same drug.

NCT06107010 — Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Sub · NA · recruiting
NCT04187209 — Evaluation of the Use of the Atalante System in Patients Presenting a Non-traumatic Hemiplegia in Acute-subacute Phase ( · NA · completed
NCT04110561 — Evaluation of Safety and Performance of the Atalante System With Patients With Lower Limb Paralysis · NA · completed

Other recruiting trials for Stroke

Currently open trials in the same condition.

NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
NCT07356011 — Exoskeleton for Balance · NA · recruiting
NCT07523503 — Unilateral Versus Bilateral Task-specific Training on Motor Impairment, Upper Extremity Function, and Hand Dexterity in · NA · recruiting
NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting

Other Wandercraft trials

Trials by the same sponsor.

NCT07536386 — Self-balancing Personal Exoskeleton for SCI (WIP) · NA · recruiting
NCT07222033 — Self-balancing Personal Exoskeleton for SCI (WINY) · NA · recruiting
NCT06814015 — Self-balancing Personal Exoskeleton for SCI (Site 2) · NA · recruiting
NCT06777576 — Self-balancing Personal Exoskeleton for SCI · NA · recruiting
NCT06715631 — Human Factors Validation Testing of the Wandercraft Personal Exoskeleton · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04694001 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wandercraft
Last refreshed: 27 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04694001.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing